Mold Exposure (Credit: Canva)
Mold is a type of fungus that has been found on the surface of the earth for millions of years. They can get inside your home through open doors, windows, and air conditioning systems. Inhaling mold spores or coming into contact with mold can have severe adverse effects on your health. Beyond physical symptoms like headache and allergic symptoms, it can have a significant impact on the brain and nervous system. Symptoms may vary, from mild headaches to more severe issues like memory loss or difficulty walking. While it can affect anybody, certain groups like children, the elderly, pregnant women, and those with weakened immune systems are particularly vulnerable to these effects.
How can mold impact your neurological health?
Mold, such as Cladophialophora bantiana, can cause infections in the brain and spinal cord, leading to serious conditions like central nervous system (CNS) infections. While such infections are rare, they can be life-threatening.
Mycotoxins are toxic chemicals produced by certain mold types. These toxins can be released into the air when mold grows indoors, and breathing them in can have direct harmful effects on brain function. Studies indicate that mycotoxins may interfere with the nervous system’s communication pathways, leading to cognitive issues such as memory problems and mood swings.
In fact, long exposure to mold can lead to a variety of neurological symptoms, which can differ depending on an individual’s health and the severity of the mold exposure. Some of them are:
Headaches are one of the most frequent symptoms of mold exposure. While most of the time, these headaches are described as dull, constant, or pressure-like, they can sometimes mimic migraines, accompanied by nausea or sensitivity to light and sound.
Exposure to molds can also trigger seizures. Mold produces toxic substances like mycotoxins that may disrupt the brain’s electrical activity, leading to seizure episodes.
Mold exposure can cause brain fog, which results in concentration, memory, and mental clarity. Studies suggest that mycotoxins can disrupt normal brain function, making it challenging to process information and think clearly.
Exposure to this fungus can also lead to emotional problems. People with this kind of exposure have complained of anxiety, depression, irritability, and sudden mood swings. This could be due to mold toxins interfering with brain chemicals responsible for regulating emotions.
Mold exposure may trigger inflammation, leading to muscle and joint pain. In case of prolonged exposure, it could lead to the development or worsening of fibromyalgia or complex regional pain syndrome (CRPS).
In some cases, mold exposure may lead to tremors, difficulty walking, or problems with muscle coordination. These issues may be linked to mycotoxins affecting the brain or nervous system.
Mold exposure can impact the brain areas responsible for movement and balance, making it harder to stand, walk, or perform fine motor tasks. Individuals may feel unsteady or experience difficulty using devices like phones or computers.
Delirium is a condition wherein a person experiences confusion or disorientation. An abnormal immune response to mold could contribute to this condition. Delirium can make it difficult for individuals to think clearly or understand their surroundings.
Credit: iStock
Metformin is a safe and effective drug used by type 2 patients for the last six decades to control their blood sugar levels and improve the way the body handles insulin.
A recent study showed that metformin can also be crucial in reducing the risk of vision loss in people over the age of 50, known as age-related macular degeneration (AMD).
The observational study, published in the BMJ Open Ophthalmology, showed that metformin can cut down the cases of AMD by nearly 40 percent in people with Type 2 diabetes over five years.
“We have found a significant association between metformin use and a reduction in the incidence of intermediate AMD by 37 percent in people with diabetes over 5 years. Previous epidemiological studies of metformin and AMD have used secondary data on AMD,” said corresponding author Nicholas A. V. Beare, from the University of Liverpool, UK.
“Given metformin’s anti-aging therapeutic effects, the reduction in risk is plausible and warrants prospective clinical trials,” he added.
Also read: Metformin Controls Blood Sugar With Help From Brain Neurons, Finds Study
While currently there is no specific treatment option for AMD — a common cause of blindness in high-income countries — scientists have shown interest in metformin as a candidate drug for treating AMD and reducing its progression.
It is because of metformin's antioxidant, anti-inflammatory, antiangiogenic, and antifibrotic effects. Metformin is also postulated to delay ageing and ageing-related diseases.
Previous research has also identified metformin as a potential treatment for all stages of AMD. Researchers also noted that the common diabetes drug is readily accessible and has a strong safety profile.
The BMJ study analyzed more than 2,500 participants aged 50 or above who attended retinopathy screening in 2011.
All participants had Type 2 diabetes and gradable fundus photographs — high-quality retinal images.
Individuals prescribed oral metformin had a 37 percent lower risk of intermediate AMD by five years. The results are consistent with known biological mechanisms, given metformin’s potential favourable effects on AMD progression, researchers reported, the researchers said.
The team, however, acknowledged limitations such as a lack of proper data regarding the dose, duration of prior use, or compliance with metformin use.
Further, there were only a relatively small number of participants developing advanced AMD – an inevitability in population-based studies. They urged for a clinical trail to prove metformin's potential in treating AMD.
Also read: World Sight Day: 10 Tips To Help Prevent Vision Loss In Elderly
Age-related macular degeneration (AMD) is a disease of the retina. It happens when a part of the retina called the macula is damaged. It results in the loss of sharp, straight-ahead vision.
The condition commonly affects adults over 50, and causes
While AMD rarely causes total blindness but affects central vision, making reading and driving difficult. It is of two types:
Credit: Instagram/Canva
Harry Potter star Daniel Radcliffe has quit smoking after 20 long years. The reason: his two–year–old son with girlfriend Erin Darke.
Speaking to media outlet Vulture, the 36-year-old English actor shared that after becoming a father, he was inspired by intrusive thoughts about his mortality, which enabled him to quit the deadly habit after two decades.
"I smoked for 20 years pretty heavily, and I was never even thinking about quitting, and then shortly after having my son, the intrusive thoughts of my own death really helped as an incentive to quit," Radcliffe was quoted as saying.
Radcliffe also shared how a book -- The Easy Way to Quit Smoking, by Alan Carr -- helped him decide to quit smoking.
"It may not work for everybody, but it really worked for me," noted the star, currently starring in the Broadway play Every Brilliant Thing.
Earlier this month, the actor spoke with WSJ Magazine and shared that from being on “cigarettes all day”, he's transformed into a fitness freak.
Smoking can affect all organs in our body. While lung cancer and tuberculosis are the most prominent ones, smoking can seriously increase the risk of several chronic diseases. These include:
While quitting tobacco is important, it is a difficult task, with some people finding it harder to quit than others. It may be important to seek help quitting.
Also read: Cigarettes And The Female Body: The Hormonal Toll We Don’t Talk About
These strategies have shown varying levels of success in aiding smokers to quit permanently. In addition, alternative methods like e-cigarettes and mindfulness-based techniques have gained traction in helping reduce smoking addiction.
Behavioral Support
Quitting smoking isn’t just about resisting cravings. Often, behavioral support through counseling or therapy is crucial for tackling the psychological aspects of addiction. Behavioral therapy involves working with a trained professional to identify triggers, develop coping strategies, and create a tailored quit plan. Research shows that combining counseling with other quit methods can significantly increase success rates.
Prescription Medications
Some medications, such as varenicline (Chantix) and bupropion (Zyban), have been shown to help people quit smoking by reducing cravings and withdrawal symptoms. Experts suggest that varenicline works by blocking the effects of nicotine in the brain, while bupropion is an antidepressant that helps manage withdrawal symptoms. Both medications are generally more effective when combined with behavioral therapy.
Nicotine Replacement Therapy (NRT)
Nicotine replacement products, such as nicotine patches, gums, lozenges, and nasal sprays, deliver controlled amounts of nicotine to ease withdrawal symptoms. According to experts at Harvard Health, NRT can double the chances of quitting by alleviating physical cravings while the person works on overcoming the psychological addiction.
Credit: Canva
About 10.6 percent –15 percent of India's population suffers from some form of mental health conditions, with 15 percent of the adult population also requiring active intervention.
To enable researchers to gather as well as systematically document data on patients with major forms of mental illness, neuroscientists in India have developed CALM-Brain — a digital repository of data on brain structure and function from a range of psychiatric disorders.
CALM-Brain contains data from over 2,000 participants from 900 families across the country.
CALM-Brain will help clinicians and researchers
“CALM-Brain was conceived as a method to assemble data from multiple scales of analysis of brain structure and function on a single platform. We believe that the application of modern methods of data analysis to this dataset will help bridge the gap between these scales of analysis,” said Prof. Raghu Padinjat, CBM co-ordinator at CBM-NCBS, in a statement.
Also read: World Happiness Report 2026 Flags Social Media Harms On Adolescents' Mental Well-being
CALM-Brain is the result of collaborative efforts of researchers at the Rohini Nilekani Centre for Brain and Mind (CBM) — a partnership between the National Institute of Mental Health and Neuro Sciences (NIMHANS) and the National Centre for Biological Sciences (NCBS) - TIFR.
CALM-Brain is India’s first-of-its-kind repository of clinical, neuroimaging, behavioral, genetic, and other datasets on disorders such as:
The dataset is also linked to a biorepository of stem cells, which can be used to perform biological research in psychiatry to understand the origins of such severe mental illnesses.
“The primary goals of the project are to identify biological markers of severe psychiatric illnesses, which cut across traditional diagnostic frameworks. In addition, we will try to identify fundamental biological mechanisms of the disease and medication response,” said Prof. Y.C. Janardhan Reddy, CBM coordinator at CBM-NIMHANS.
Mental wellness is a major health and economic concern in India. The World Health Organization (WHO) estimates India’s economic loss due to mental health conditions to be USD 1.03 trillion (2012-2030).
Recently, health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.
"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.
They added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)" among citizens.
To address the rising burden, the government aims to launch NIMHANS-2 — first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27 — to deliver specialized care for mental health and neurological disorders in north India.
"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," FM Sitharaman said.
© 2024 Bennett, Coleman & Company Limited